56 related articles for article (PubMed ID: 9139528)
1. [Factors influencing variability of PSA blood concentration in patients with prostate benign hyperplasia].
Sanz Chinesta S; Martínez Jabaloyas JM; Boronat Tormo F; Martínez Sarmiento M; Jiménez Cruz JF
Actas Urol Esp; 1996; 20(10):867-72. PubMed ID: 9139528
[TBL] [Abstract][Full Text] [Related]
2. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia.
Lee SE; Chung JS; Han BK; Moon KH; Hwang SI; Lee HJ; Choe G; Hong SK
Urology; 2008 Mar; 71(3):395-8. PubMed ID: 18342171
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
4. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
5. Effect of transurethral indwelling catheter on serum prostate-specific antigen level in benign prostatic hyperplasia.
Batislam E; Arik AI; Karakoc A; Uygur MC; Germiyanoğlu RC; Erol D
Urology; 1997 Jan; 49(1):50-4. PubMed ID: 9000185
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between serum PSA and prostate volume in benign hyperplasia].
Ojea Calvo A; Rodrigo AA; Verez Vivero MM; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; Nogueira March JL
Actas Urol Esp; 1994 Mar; 18(3):178-80. PubMed ID: 7518640
[TBL] [Abstract][Full Text] [Related]
7. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
8. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
[TBL] [Abstract][Full Text] [Related]
9. [PSA/volume ratio in prostatic disease in the elderly].
Bo M; Ventura M; Massaia M; Fabris F
Recenti Prog Med; 2001 Oct; 92(10):594-8. PubMed ID: 11695303
[TBL] [Abstract][Full Text] [Related]
10. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
11. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
12. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
14. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
[TBL] [Abstract][Full Text] [Related]
16. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.
Bohnen AM; Groeneveld FP; Bosch JL
Eur Urol; 2007 Jun; 51(6):1645-52; discussion 1652-3. PubMed ID: 17320271
[TBL] [Abstract][Full Text] [Related]
17. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
[TBL] [Abstract][Full Text] [Related]
18. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
[TBL] [Abstract][Full Text] [Related]
19. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
20. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]